Clinical Trial Update: Upadacitinib Versus IL-17 Inhibitors in Patients With Psoriatic Arthritis

View source ↗

Summary

A completed clinical trial comparing upadacitinib with IL-17 inhibitors in patients with psoriatic arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Ixekizumab (ixekizumab)
• Secukinumab (secukinumab)
• Upadacitinib (upadacitinib)
• brodalumab (brodalumab)

Snippet

Sponsor: Peking University First Hospital | Conditions: Psoriatic Arthritis, Upadacitinib | Status: COMPLETED